Featured Companies
Hyperdynamics, HDY, Profile, Summary
Hyperdynamics | HDY | Profile | Summary
Hyperdynamics' new management team began accelerating exploration activities on the Guinea concession in mid-2009, our strategy has been to maximize shareholder value by retaining as large a working interest ownership position in the concession as possible, for as long as possible.
To fund its ongoing exploration activities during this period, Hyperdynamics successfully raised more than $220 million of equity from institutional investors, and nearly a quarter of its outstanding common shares are held by institutions.
In early 2010, Hyperdynamics sold a 23% stake in the Guinea project to Dana Petroleum for a total of $19.6 million, which allowed the Company to retain a 77% working interest in and operatorship of the project as it spudded the first exploration well in late 2011, the Sabu-1.
The Sabu-1 exploration well encountered oil shows while drilling the targeted Upper Cretaceous section, and our well-log interpretations indicated the presence of residual oil in non-commercial quantities. Following the drilling of the Sabu-1 well, Hyperdynamics was able to attract a world class independent explorer, Tullow Oil, to join as partner and operator of future exploration activities. Following the sale to Tullow, Hyperdynamics still retains a 37% working interest in the Guinea concession
Summary and outlook of future O&G
Deepwater Production
>>limited mainly to basins of Atlantic Margin
Common factors:
•World class source rocks
•Continuous subsidence and deposition
Differentiating factors for mega provinces
•Presence of massive salt
•Major river systems for sediment inputCumulative Reserves estimated 160 BB0 of which 115 BBO have been discovered Production peaks at 11-12 MMBOD in decade of 2020-2030
Heavy Oil Production
• Production reaches 7 MMBOD in 2030
>>85% of resources in two provinces
•High oil prices needed for profitability
•Heaviest environmental footprint (surface imprint, CO2 emission, water use) of
unconventional production
•Better commercial environment in Canada vs. Venezuela makes Canada leader in production and technology despite better reservoir and oil quality in Venezuela
Shale Oil Production by hydraulic fracturing
Significant production initiated in 2010 utilizing combination of fracking and horizontal drillingEconomics dominated by high well decline rates and need for extensive infrastructure. While potential high potential formations can be found worldwide, significant production only started in USA for mainly non-technical reasons
Shale Oil Production Increase: How much and how fast?
USA Production: (not including NGL’s)
Major plays
Bakken and Eagle Ford should plateau at about 1.0 and 1.2 MMBOD for 5 years
before declining.
•Permian a combination of shale and conventional plays
•Other shale plays an order of magnitude smaller
•NGL’s major part of play, as they are needed to make most gas shale plays economic
•Combination of crude oil and NGL’s will add about 5 MMBOD to US production in the 2015-2020 period.
New Oil World
•Non renewable conventional production peaked in 2005
and is rapidly being replaced by high cost deep water and unconventional oil
•Remaining conventional production focused in the Arabian Basin and FSU, while
new production mostly in Western Hemisphere and Sub Saharan Africa
•World production growth slows in 2020’s when deep water production peaks, and next
price spike a possibility
Sub Saharan Africa
•Production doubles in the 2000-2020 time period
•Low cost conventional oil largely replaced by high cost deep water oil
•Despite increased production, revenue per barrel is approximately half; without recognizing fiscal reality, necessary investment will not be attracted
•After 2020, production will gradually shift from current SW Africa hub to new
provinces in NW Africa and East Africa
Sources: The company, OxBridge Research, OTCKING, DailyStockDeals, OTCstockIQ
Don't miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@] OxBridgeResearch.com
Hemispherx Biopharma, HEB, Profile, Summary
Hemispherx Biopharma, HEB, Profile, Summary
Hemispherx Biopharma, HEB, is a biopharmaceutical company dedicated to treating and preventing chronic viral and immune-based disorders through the development and manufacturing of compounds that enhance the natural immune system of the human body. Hemispherx Biopharma, has developed over nearly three decades a vast body of knowledge relating to a potentially new class of pharmaceutical products (nucleic acid compounds) that are designed to activate otherwise dormant cellular defenses against viruses and tumors.
The Company’s flagship products include Alferon N Injection® and the experimental immunotherapeutics Ampligen®. Its platform technology includes large and small agents for potential treatment of various chronic viral infections.
Ampligen®, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted at such important diseases as Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, and cancers including kidney cancer and metastatic malignant melanoma.
Alferon N Injection® (interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multi-species alpha interferon product, composed of eight forms of high-purified alpha interferon. It is the only natural source, multi-species alfa interferon currently sold in the United States and is also approved for sale Argentina. Alferon N Injection® is the company’s registered trademark for it’s injectible formulation or natural alpha interferon approved by the FDA for the treatment of genital HPV (refractory condylomata acuminata). Alferon N Injection® may also have activity against other viral infections such as Multiple Sclerosis, Hepatitis C, HIV, West Nile Virus, and SARS, but has not been approved for that use.
Ampligen®
Ampligen®, the company's lead compound addresses a variety of chronic diseases and viral disorders. Ampligen® drugs for several viral disorders are under development. More than 40,000 doses at over 20 U.S. clinical trial sites have been delivered with Ampligen®.
ALFERON N Injection®
ALFERON N Injection® [Interferon alfa-n3 (human leukocyte derived)] is the Company's registered trademark for its injectable formulation of Natural Alpha Interferon, approved by the U.S. Food and Drug Administration (FDA) for the intralesional treatment of refractory or recurring external condylomata acuminata in patients 18 years of age or older.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
-
All warts disappeared in 54% of patients.3
-
No recurrence in 76% of complete responders at follow-up.3
-
Completely cleared 73% of all treated warts.3,4
-
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
-
Provides a spectrum of multiple alpha interferon subtypes.1,2
Well-tolerated
-
No surgery or caustics and resultant ulceration or scarring.
-
No specific post-treatment care necessary.4
-
The most common adverse effects (mild to moderate, transient flu-like symptoms) were comparable to placebo after 304 weeks of therapy.3.4
-
The majority of patients considered Alferon N Injection preferable to conventional therapy. 3.4
Please see the package insert for prescribing information.
Alferon Low Dose Oral (LDO)®
Alferon LDO®, Hemispherx's oral form of Our Anferon N product (Low Dose Oral Interferon Alfa-N3, Human Leukocyte Derived), which is a new delivery form of our FDA approved drug, Alferon N® is the only natural interferon currently FDA approved and available in the marketplace. Hemispherx has initiated clinical trials as part of an accelerated evaluation of the experimental bio-therapeutic Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) as a potential new experimental therapy for Avian Flu and other lethal viral diseases, which have high acute death rates. Clinical trials in human volunteers (being conducted in both the U.S. at Drexel University, Philadelphia, and shortly to commence in Hong Kong at the Princess Margaret Hospital) are designed to determine whether Alferon N, delivered in a new, experimental oral drug delivery format, can resuscitate the broad-spectrum antiviral and immunostimulatory genes. These human genes are shut down by acute lethal viral infections such as avian flu and smallpox
Sources: The Company, OxBridge Research, Daily Stock Deals, Penny Stock Monster, OTC King
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have questions/comments, please don't hesitate to contact the Editor [@ ] OxBridgeResearch.com
HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis, influenza, H5N1, H7N9, avian influenza, drug resistant avian influenza, Hepatitis A, viral, bacterial, viral infections, Multiple Sclerosis, Hepatitis C, West Nile Virus, SARS, FDA. CIDC.
Bacterin International, BONE, Profile, Summary
Bacterin International, BONE, Profile, Summary
Bacterin International Holdings (NYSE: BONE), a developer of bioactive coatings for medical applications and revolutionary bone graft material, processes and markets innovative, biologic allografts for transplantation. The Company’s biologic scaffolds, OsteoSponge®, OsteoSponge® SC and OsteoWrap®, are made from demineralized bone that is malleable and flexible, which enables more efficient and precise handling. It also markets BacFast® and OsteoLock®, which are used in spine surgery, designed to minimize graft back-out, and increase osteoinductivity. Bacterin's latest allograft, OsteoSelect® DBM Putty has excellent handling characteristics and is distributed as a sterile product, with osteoinductivity testing completed on every lot after terminal sterilization.
Bacterin’s Medical Device and Coatings Division focuses on the development of bioactive coating technologies for implantable devices. It’s core competency is anti-microbial coatings designed to reduce potential infections associated with implants, thus improving rates of healthcare-associated infections and associated costs. This Division also manages surgical kits necessary to support implantation of products processed by Bacterin’s Biologics Division.
Bacterin is an accredited tissue bank and medical device company that designs, processes, manufactures, and markets advanced medical products. Using designs focused on efficacy and safety for the patient, and functionality and ease of use for the surgeon. Bacterin is a specialty tissue bank focused on processing and distributing quality, cost-effective allografts. Bacterin operates a 32,000 sq. ft., state-of-the-art, fully compliant and FDA registered facility, equipped with five "Class 100" clean room
Sources: The Company, OxBridge Research, Daily Stock Deals, Penny Stock Monster, OTC King
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Bone, skin, sking grafts, plastic surgery, osteo sponge, biologics, bone grafts, osteeporosis. Menopause, post menopause, Bacterin, natural medical devices.
U.S. Geothermal, HTM, Profile
U.S. Geothermal | HTM | Profile | Summary
Major Highlights
•Traded on NYSE: HTM and TSX: GTH
•Transitioned from development company to Independent Power Producer
•Proven management team
•10+years of successful project development and growth
→ 3 modern geothermal power plants, plus two advanced development projects
•65 MW gross generating capacity online during 2012
•Valuable, non-depleting energy from the earth
>>•Achieved positive net income, cash flow, and EBITDA
>>>2013 first year of sustainable earnings & cash flows
----->>>•Buying opportunity- Under valued stock
Vision: Building a sustainable, long-term clean
Management: Proven geothermal energy development and operating experience
Assets: Three operating geothermal power plants
•22 MW Neal Hot Springs plant Vale, Oregon •9 MW San Emidio plant near Reno, Nevada
•13 MW Raft River plant near Pocatello,Idaho.
Advanced development properties:
•El Ceibillo near Guatemala City Guatemala •San Emidio II near Reno, Nevada
Geothermal Power Background
•Produced by utilizing heat that naturally exists within the Earth’s crust
•National Renewable Energy Lab (NREL) estimates that heat within 10,000 meters of earth’s surface is 50,000 times greater than energy that is available from petroleum and natural gas
•Geological anomalies create “shallow”reservoirs of geothermal fluids (steam and water) that can be economically exploited
•Typically reservoirs are 1,000 – 12,000 feet deep
•Geothermal fluids act as heat carriers. Those fluids are piped to the surface and used to drive turbine generators
•Geothermal fluid is reinjected to sustain reservoir pressure
•Geothermal power is renewable without significant output deterioration over time
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Sources: US Geothermal, OxBridgeResearch, OTCking, DailyStockDeal
Geothermal power, non depleting sources, renewable sources, renewable energy labs, geothermal power plants. Sustainable, bio energy